Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Monopar Therapeutics
Report date September 30, 2026 · Filed October 02, 2026
Section 16 reporting ended · disclosed 2025-09-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 104,724 |
Ending reported balance
After 2026-09-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-30 · Exercise / conversion · Acquired 9,801 · Balance 109,068 F1: Represents shares acquired on vesting and settlement of restricted stock units. Row 2 · 2026-09-30 · Tax withholding · Disposed 4,344 · Balance 104,724 F2: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 83,602 |
Reported balance
After 2026-09-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-30 · Exercise / conversion · Disposed 9,801 · Balance 83,602 F1: Represents shares acquired on vesting and settlement of restricted stock units. F4: On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5: On March 4, 2025, the reporting person was granted 79,899 restricted stock units of which 6,002 shares vested immediately as of the grant date. The remaining 73,897 restricted stock units vest 6/48ths (9,237 shares) on June 30, 2025, and 3/48ths (4,619 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F6: On December 2, 2025, the reporting person was granted 49,133 restricted stock units, vesting 6/48ths (6,142) on June 30, 2026, and 3/48ths (3,071 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 62,815 |
Reported balance
Holding disclosure · report date 2026-09-30 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 62,815 F3: Represents shares held by the Chandler D. Robinson Irrevocable Trust U/A dated May 20, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares acquired on vesting and settlement of restricted stock units.
F2: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.
F3: Represents shares held by the Chandler D. Robinson Irrevocable Trust U/A dated May 20, 2020.
F4: On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
F5: On March 4, 2025, the reporting person was granted 79,899 restricted stock units of which 6,002 shares vested immediately as of the grant date. The remaining 73,897 restricted stock units vest 6/48ths (9,237 shares) on June 30, 2025, and 3/48ths (4,619 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
F6: On December 2, 2025, the reporting person was granted 49,133 restricted stock units, vesting 6/48ths (6,142) on June 30, 2026, and 3/48ths (3,071 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2026 Filed Oct 2, 2026 22:14 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Unit · Derivative | 9,801 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-031925 · rdgdoc.xml · derivative · entry 4 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,602 Underlying: Common Stock · 9,801 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F4 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.exercise_date: On March 4, 2025, the reporting person was granted 79,899 restricted stock units of which 6,002 shares vested immediately as of the grant date. The remaining 73,897 restricted stock units vest 6/48ths (9,237 shares) on June 30, 2025, and 3/48ths (4,619 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F6 · derivative.exercise_date: On December 2, 2025, the reporting person was granted 49,133 restricted stock units, vesting 6/48ths (6,142) on June 30, 2026, and 3/48ths (3,071 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.expiration_date: On March 4, 2025, the reporting person was granted 79,899 restricted stock units of which 6,002 shares vested immediately as of the grant date. The remaining 73,897 restricted stock units vest 6/48ths (9,237 shares) on June 30, 2025, and 3/48ths (4,619 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F6 · derivative.expiration_date: On December 2, 2025, the reporting person was granted 49,133 restricted stock units, vesting 6/48ths (6,142) on June 30, 2026, and 3/48ths (3,071 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| September 30, 2026 Filed Oct 2, 2026 22:14 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 4,344 | $79.67 | $346,086.48 |
DisclosureSEC source: 0001437749-26-031925 · rdgdoc.xml · nonDerivative · entry 2 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,724 F2 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. Read SEC document |
| September 30, 2026 Filed Oct 2, 2026 22:14 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 9,801 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-26-031925 · rdgdoc.xml · nonDerivative · entry 1 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,068 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| September 24, 2026 Filed Sep 29, 2026 00:47 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionStock Option · Derivative | 15,000 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001437749-26-031411 · rdgdoc.xml · derivative · entry 9 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,204 Underlying: Common Stock · 15,000 shares Expires 2032-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on June 25, 2026. F3 · derivative.exercise_date: On February 2, 2022, the reporting person was granted stock options to purchase up to 42,204 shares of common stock. Stock options vest 6/48ths on June 30, 2022 and 1/48ths per month thereafter. Read SEC document |
| September 24, 2026 Filed Sep 29, 2026 00:47 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionStock Option · Derivative | 14,056 | $0.00 Strike: $30.00 | $0.00 |
DisclosureSEC source: 0001437749-26-031411 · rdgdoc.xml · derivative · entry 8 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,044 Underlying: Common Stock · 14,056 shares Expires 2028-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on June 25, 2026. F2 · derivative.exercise_date: On August 9, 2018, the reporting person was granted stock options to purchase up to 29,100 shares of common stock. Stock options vest 6/51 on the six-month anniversary of vesting commencement date of October 1, 2018 and 1/51 per month thereafter. Read SEC document |
| September 24, 2026 Filed Sep 29, 2026 00:47 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon Stock | 600 | $89.79 | $53,874.00 |
DisclosureSEC source: 0001437749-26-031411 · rdgdoc.xml · nonDerivative · entry 6 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,267 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on June 25, 2026. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.56 to $89.91, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) through (8) to this Form 4. Read SEC document |
| September 24, 2026 Filed Sep 29, 2026 00:47 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon Stock | 8,368 | $88.97 | $744,500.96 |
DisclosureSEC source: 0001437749-26-031411 · rdgdoc.xml · nonDerivative · entry 5 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,867 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on June 25, 2026. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.54 to $89.51, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) through (8) to this Form 4. Read SEC document |
| September 24, 2026 Filed Sep 29, 2026 00:47 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon Stock | 9,638 | $87.96 | $847,758.48 |
DisclosureSEC source: 0001437749-26-031411 · rdgdoc.xml · nonDerivative · entry 4 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 108,235 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on June 25, 2026. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.54 to $88.53, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) through (8) to this Form 4. Read SEC document |
| September 24, 2026 Filed Sep 29, 2026 00:47 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon Stock | 10,450 | $87.15 | $910,717.50 |
DisclosureSEC source: 0001437749-26-031411 · rdgdoc.xml · nonDerivative · entry 3 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,873 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on June 25, 2026. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.54 to $87.53, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) through (8) to this Form 4. Read SEC document |
| September 24, 2026 Filed Sep 29, 2026 00:47 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 15,000 | $14.00 | $210,000.00 |
DisclosureSEC source: 0001437749-26-031411 · rdgdoc.xml · nonDerivative · entry 2 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 128,323 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on June 25, 2026. Read SEC document |
| September 24, 2026 Filed Sep 29, 2026 00:47 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 14,056 | $30.00 | $421,680.00 |
DisclosureSEC source: 0001437749-26-031411 · rdgdoc.xml · nonDerivative · entry 1 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 113,323 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on June 25, 2026. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 23:38 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Unit · Derivative | 12,873 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-022630 · rdgdoc.xml · derivative · entry 4 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,403 Underlying: Common Stock · 12,873 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F4 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.exercise_date: On March 4, 2025, the reporting person was granted 79,899 restricted stock units of which 6,002 shares vested immediately as of the grant date. The remaining 73,897 restricted stock units vest 6/48ths (9,237 shares) on June 30, 2025, and 3/48ths (4,619 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F6 · derivative.exercise_date: On December 2, 2025, the reporting person was granted 49,133 restricted stock units, vesting 6/48ths (6,142) on June 30, 2026, and 3/48ths (3,071 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.expiration_date: On March 4, 2025, the reporting person was granted 79,899 restricted stock units of which 6,002 shares vested immediately as of the grant date. The remaining 73,897 restricted stock units vest 6/48ths (9,237 shares) on June 30, 2025, and 3/48ths (4,619 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F6 · derivative.expiration_date: On December 2, 2025, the reporting person was granted 49,133 restricted stock units, vesting 6/48ths (6,142) on June 30, 2026, and 3/48ths (3,071 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 23:38 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 4,084 | $92.59 | $378,137.56 |
DisclosureSEC source: 0001437749-26-022630 · rdgdoc.xml · nonDerivative · entry 2 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,267 F2 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 23:38 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 12,873 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-26-022630 · rdgdoc.xml · nonDerivative · entry 1 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 19:03 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Unit · Derivative | 6,732 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-011079 · rdgdoc.xml · derivative · entry 4 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,276 Underlying: Common Stock · 6,732 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F4 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.exercise_date: On March 4, 2025, the reporting person was granted 79,899 restricted stock units of which 6,002 shares vested immediately as of the grant date. The remaining 73,897 restricted stock units vest 6/48ths (9,237 shares) on June 30, 2025, and 3/48ths (4,619 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.expiration_date: On March 4, 2025, the reporting person was granted 79,899 restricted stock units of which 6,002 shares vested immediately as of the grant date. The remaining 73,897 restricted stock units vest 6/48ths (9,237 shares) on June 30, 2025, and 3/48ths (4,619 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 19:03 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 1,972 | $54.79 | $108,045.88 |
DisclosureSEC source: 0001437749-26-011079 · rdgdoc.xml · nonDerivative · entry 2 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,478 F2 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 19:03 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 6,732 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-26-011079 · rdgdoc.xml · nonDerivative · entry 1 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 20:46 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Unit · Derivative | 8,724 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-000306 · rdgdoc.xml · derivative · entry 4 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,008 Underlying: Common Stock · 8,724 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F4 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 31,905 restricted stock units, vesting 6/48ths (3,988 shares) on June 30, 2022, and 3/48ths (1,994 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F6 · derivative.exercise_date: On March 4, 2025, the reporting person was granted 79,899 restricted stock units of which 6,002 shares vested immediately as of the grant date. The remaining 73,897 restricted stock units vest 6/48ths (9,237 shares) on June 30, 2025, and 3/48ths (4,619 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 31,905 restricted stock units, vesting 6/48ths (3,988 shares) on June 30, 2022, and 3/48ths (1,994 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F6 · derivative.expiration_date: On March 4, 2025, the reporting person was granted 79,899 restricted stock units of which 6,002 shares vested immediately as of the grant date. The remaining 73,897 restricted stock units vest 6/48ths (9,237 shares) on June 30, 2025, and 3/48ths (4,619 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 20:46 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 2,558 | $65.30 | $167,037.40 |
DisclosureSEC source: 0001437749-26-000306 · rdgdoc.xml · nonDerivative · entry 2 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,718 F2 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 20:46 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 8,724 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-26-000306 · rdgdoc.xml · nonDerivative · entry 1 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,276 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| December 02, 2025 Filed Dec 8, 2025 21:46 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantRestricted Stock Units · Derivative | 49,133 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-037163 · rdgdoc.xml · derivative · entry 2 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,732 Underlying: Common Stock · 49,133 shares Expires not disclosed F2 · derivative.exercise_date: RSUs vest 6/48ths on June 30, 2026, and 3/48ths per quarter thereafter. F2 · derivative.expiration_date: RSUs vest 6/48ths on June 30, 2026, and 3/48ths per quarter thereafter. Read SEC document |
| December 02, 2025 Filed Dec 8, 2025 21:46 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 16,753 | $0.00 Strike: $75.94 | $0.00 |
DisclosureSEC source: 0001437749-25-037163 · rdgdoc.xml · derivative · entry 1 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,753 Underlying: Common Stock · 16,753 shares Expires 2035-12-02 F1 · derivative.exercise_date: Options vest 6/48ths on June 30, 2026, and 1/48th per month thereafter. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 19:04 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 8,726 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-030284 · rdgdoc.xml · derivative · entry 4 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,599 Underlying: Common Stock · 8,726 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F4 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 31,905 restricted stock units, vesting 6/48ths (3,988 shares) on June 30, 2022, and 3/48ths (1,994 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F6 · derivative.exercise_date: On March 4, 2025, the reporting person was granted 79,899 restricted stock units of which 6,002 shares vested immediately as of the grant date. The remaining 73,897 restricted stock units vest 6/48ths (9,237 shares) on June 30, 2025, and 3/48ths (4,619 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 31,905 restricted stock units, vesting 6/48ths (3,988 shares) on June 30, 2022, and 3/48ths (1,994 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F6 · derivative.expiration_date: On March 4, 2025, the reporting person was granted 79,899 restricted stock units of which 6,002 shares vested immediately as of the grant date. The remaining 73,897 restricted stock units vest 6/48ths (9,237 shares) on June 30, 2025, and 3/48ths (4,619 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 19:04 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 2,646 | $81.67 | $216,098.82 |
DisclosureSEC source: 0001437749-25-030284 · rdgdoc.xml · nonDerivative · entry 2 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,552 F2 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 19:04 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 8,726 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-25-030284 · rdgdoc.xml · nonDerivative · entry 1 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,198 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| September 24, 2025 Filed Sep 26, 2025 15:53 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon Stock | 550,229 | $63.61 | $34,999,956.64 |
DisclosureSEC source: 0001437749-25-029925 · rdgdoc.xml · nonDerivative · entry 1 Tactic Pharma LLC · CIK 0001727357 · 10% owner Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer Brown Michael J · CIK 0001035909 · Member of 10% Owner Group O'Halloran Thomas V. · CIK 0001727481 · Member of 10% Owner Group Mazar Andrew Paul · CIK 0001727393 · Member of 10% Owner Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 272,026 F1 · ownership.direct: This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein. The Reporting Persons are no longer subject to Section 16, except for Chandler D. Robinson, who serves as Chief Executive Officer of Monopar Therapeutics Inc. Read SEC document |
| July 14, 2025 Filed Jul 17, 2025 01:02 UTC | Monopar Therapeutics MNPR · Entity 5152 | OtherStock Options · Derivative | 16,800 | $0.00 Strike: $0.01 | $0.00 |
DisclosureSEC source: 0001437749-25-022861 · rdgdoc.xml · derivative · entry 4 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,800 shares Expires 2027-02-20 F4 · derivative.exercise_date: Reflects options to purchase up to 16,800 shares of common stock granted to Dr. Robinson on February 20, 2017, for his services as a director and officer of Monopar Therapeutics. The options vested 6/48ths upon the 6-month anniversary of the grant date and 1/48th per month thereafter. Read SEC document |
| July 14, 2025 Filed Jul 17, 2025 01:02 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon Stock | 16,800 | $40.00 | $672,020.16 |
DisclosureSEC source: 0001437749-25-022861 · rdgdoc.xml · nonDerivative · entry 2 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,472 F2 · price: The shares were sold in multiple transactions at prices ranging from $40.00 to $40.25, inclusive. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| July 14, 2025 Filed Jul 17, 2025 01:02 UTC | Monopar Therapeutics MNPR · Entity 5152 | OtherCommon Stock | 16,800 | $0.01 | $84.00 |
DisclosureSEC source: 0001437749-25-022861 · rdgdoc.xml · nonDerivative · entry 1 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,272 F1 · shares: This transaction involved a cash exercise of stock options. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:25 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 13,344 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-021994 · rdgdoc.xml · derivative · entry 4 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,325 Underlying: Common Stock · 13,344 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F4 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 31,905 restricted stock units, vesting 6/48ths (3,988 shares) on June 30, 2022, and 3/48ths (1,994 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F6 · derivative.exercise_date: On March 4, 2025, the reporting person was granted 79,899 restricted stock units of which 6,002 shares vested immediately as of the grant date. The remaining 73,897 restricted stock units vest 6/48ths (9,237 shares) on June 30, 2025, and 3/48ths (4,619 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 31,905 restricted stock units, vesting 6/48ths (3,988 shares) on June 30, 2022, and 3/48ths (1,994 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F6 · derivative.expiration_date: On March 4, 2025, the reporting person was granted 79,899 restricted stock units of which 6,002 shares vested immediately as of the grant date. The remaining 73,897 restricted stock units vest 6/48ths (9,237 shares) on June 30, 2025, and 3/48ths (4,619 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:25 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 5,865 | $35.78 | $209,849.70 |
DisclosureSEC source: 0001437749-25-021994 · rdgdoc.xml · nonDerivative · entry 2 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,472 F2 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:25 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 13,344 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-25-021994 · rdgdoc.xml · nonDerivative · entry 1 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,337 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| April 02, 2025 Filed Apr 4, 2025 19:27 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon Stock | 33,334 | $35.00 | $1,166,690.00 |
DisclosureSEC source: 0001437749-25-011068 · rdgdoc.xml · nonDerivative · entry 1 Tactic Pharma LLC · CIK 0001727357 · 10% owner Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer Brown Michael J · CIK 0001035909 · Member of 10% Owner Group O'Halloran Thomas V. · CIK 0001727481 · Member of 10% Owner Group Mazar Andrew Paul · CIK 0001727393 · Member of 10% Owner Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 822,255 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.86, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · ownership.direct: This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein. Read SEC document |
| March 31, 2025 Filed Apr 3, 2025 01:07 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 4,106 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-010809 · rdgdoc.xml · derivative · entry 4 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,669 Underlying: Common Stock · 4,106 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F4 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 31,905 restricted stock units, vesting 6/48ths (3,988 shares) on June 30, 2022, and 3/48ths (1,994 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 31,905 restricted stock units, vesting 6/48ths (3,988 shares) on June 30, 2022, and 3/48ths (1,994 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| March 31, 2025 Filed Apr 3, 2025 01:07 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 1,204 | $36.41 | $43,837.64 |
DisclosureSEC source: 0001437749-25-010809 · rdgdoc.xml · nonDerivative · entry 2 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,993 F2 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. Read SEC document |
| March 31, 2025 Filed Apr 3, 2025 01:07 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 4,106 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-25-010809 · rdgdoc.xml · nonDerivative · entry 1 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,197 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| March 04, 2025 Filed Mar 8, 2025 02:24 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 6,002 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-006736 · rdgdoc.xml · derivative · entry 6 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,775 Underlying: Common Stock · 6,002 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F6 · derivative.exercise_date: Represents vesting of 6,002 restricted stock units on the grant date. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F6 · derivative.expiration_date: Represents vesting of 6,002 restricted stock units on the grant date. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| March 04, 2025 Filed Mar 8, 2025 02:24 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantRestricted Stock Units · Derivative | 79,899 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-006736 · rdgdoc.xml · derivative · entry 5 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,777 Underlying: Common Stock · 79,899 shares Expires not disclosed F4 · derivative.exercise_date: 6,002 restricted stock units vested on the grant date. Remainder of restricted stock units vest 6/48ths on June 30, 2025, and 3/48ths per quarter thereafter. F4 · derivative.expiration_date: 6,002 restricted stock units vested on the grant date. Remainder of restricted stock units vest 6/48ths on June 30, 2025, and 3/48ths per quarter thereafter. Read SEC document |
| March 04, 2025 Filed Mar 8, 2025 02:24 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 85,759 | $0.00 Strike: $31.70 | $0.00 |
DisclosureSEC source: 0001437749-25-006736 · rdgdoc.xml · derivative · entry 4 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,759 Underlying: Common Stock · 85,759 shares Expires 2035-03-04 F3 · derivative.exercise_date: 6,647 options vested on the grant date. Remainder of options vest 6/48ths on June 30, 2025, and 1/48th per month thereafter. Read SEC document |
| March 04, 2025 Filed Mar 8, 2025 02:24 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 1,759 | $31.70 | $55,760.30 |
DisclosureSEC source: 0001437749-25-006736 · rdgdoc.xml · nonDerivative · entry 2 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,091 F2 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. Read SEC document |
| March 04, 2025 Filed Mar 8, 2025 02:24 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 6,002 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-25-006736 · rdgdoc.xml · nonDerivative · entry 1 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,850 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| January 28, 2025 Filed Jan 30, 2026 19:31 UTC | Monopar Therapeutics MNPR · Entity 5152 | OtherCommon Stock | 62,815 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-002527 · rdgdoc.xml · nonDerivative · entry 2 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 62,815 F1 · kind: Pro rata liquidating distribution from Tactic Pharma, LLC ("Tactic"), of which the reporting person is a non-controlling member. In prior reports, the reporting person reported beneficial ownership of 272,026 shares of Monopar Therapeutics Inc. common stock held by Tactic. F2 · ownership.nature: Represents shares held by the Chandler D. Robinson Irrevocable Trust U/A dated May 20, 2020. Read SEC document |
| December 31, 2024 Filed Jan 2, 2025 23:14 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 4,895 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-000096 · rdgdoc.xml · derivative · entry 4 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,879 Underlying: Common Stock · 4,895 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F4 · derivative.exercise_date: On January 26, 2021, the reporting person was granted 12,612 restricted stock units, vesting 6/48ths (1,577 shares) on June 30, 2021, and 3/48ths (788 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 31,905 restricted stock units, vesting 6/48ths (3,988 shares) on June 30, 2022, and 3/48ths (1,994 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F6 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On January 26, 2021, the reporting person was granted 12,612 restricted stock units, vesting 6/48ths (1,577 shares) on June 30, 2021, and 3/48ths (788 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 31,905 restricted stock units, vesting 6/48ths (3,988 shares) on June 30, 2022, and 3/48ths (1,994 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F6 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| December 31, 2024 Filed Jan 2, 2025 23:14 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 2,209 | $22.00 | $48,598.00 |
DisclosureSEC source: 0001437749-25-000096 · rdgdoc.xml · nonDerivative · entry 2 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,848 F2 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. Read SEC document |
| December 31, 2024 Filed Jan 2, 2025 23:14 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 4,895 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-25-000096 · rdgdoc.xml · nonDerivative · entry 1 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 23:45 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 4,895 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-030536 · rdgdoc.xml · derivative · entry 5 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,774 Underlying: Common Stock · 4,895 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F1 · derivative.exercise_date: Effective on August 12, 2024, Monopar Therapeutics Inc effected a 5 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split F6 · derivative.exercise_date: On January 26, 2021, the reporting person was granted 12,612 restricted stock units, vesting 6/48ths (1,577 shares) on June 30, 2021, and 3/48ths (788 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F7 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 31,905 restricted stock units, vesting 6/48ths (3,988 shares) on June 30, 2022, and 3/48ths (1,994 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F8 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F6 · derivative.expiration_date: On January 26, 2021, the reporting person was granted 12,612 restricted stock units, vesting 6/48ths (1,577 shares) on June 30, 2021, and 3/48ths (788 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F7 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 31,905 restricted stock units, vesting 6/48ths (3,988 shares) on June 30, 2022, and 3/48ths (1,994 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F8 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 23:45 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 1,918 | $6.74 | $12,927.32 |
DisclosureSEC source: 0001437749-24-030536 · rdgdoc.xml · nonDerivative · entry 2 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,162 F3 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 23:45 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 4,895 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-24-030536 · rdgdoc.xml · nonDerivative · entry 1 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,080 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| June 30, 2024 Filed Jul 2, 2024 22:07 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 24,476 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-022023 · rdgdoc.xml · derivative · entry 5 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,335 Underlying: Common Stock · 24,476 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F5 · derivative.exercise_date: On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F6 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 159,522 restricted stock units, vesting 6/48ths (19,940 shares) on June 30, 2022, and 3/48ths (9,970 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F7 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 169,012 restricted stock units, vesting 6/48ths (21,127 shares) on June 30, 2023, and 3/48ths (10,563 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.expiration_date: On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F6 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 159,522 restricted stock units, vesting 6/48ths (19,940 shares) on June 30, 2022, and 3/48ths (9,970 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F7 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 169,012 restricted stock units, vesting 6/48ths (21,127 shares) on June 30, 2023, and 3/48ths (10,563 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| June 30, 2024 Filed Jul 2, 2024 22:07 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 8,684 | $0.73 | $6,348.00 |
DisclosureSEC source: 0001437749-24-022023 · rdgdoc.xml · nonDerivative · entry 2 Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 265,922.8 F2 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.